Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML
Andreas T. Björklund, Mattias Carlsten, Ebba Sohlberg, et al.
Clinical Cancer Research (2018) Vol. 24, Iss. 8, pp. 1834-1844
Open Access | Times Cited: 158

Showing 1-25 of 158 citing articles:

Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion
Suchit Jhunjhunwala, Christian Hammer, Lélia Delamarre
Nature reviews. Cancer (2021) Vol. 21, Iss. 5, pp. 298-312
Closed Access | Times Cited: 989
NK cells for cancer immunotherapy
Noriko Shimasaki, Amit Jain, Dario Campana
Nature Reviews Drug Discovery (2020) Vol. 19, Iss. 3, pp. 200-218
Closed Access | Times Cited: 973
Natural Killer Cells: Development, Maturation, and Clinical Utilization
Alex M. Abel, Chao Yang, Monica S. Thakar, et al.
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 945
The NK cell–cancer cycle: advances and new challenges in NK cell–based immunotherapies
Tobias Bald, Matthew F. Krummel, Mark J. Smyth, et al.
Nature Immunology (2020) Vol. 21, Iss. 8, pp. 835-847
Open Access | Times Cited: 378
Pluripotent stem cell–derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity
Zhu Huang, Robert Blum, Ryan Bjordahl, et al.
Blood (2019) Vol. 135, Iss. 6, pp. 399-410
Open Access | Times Cited: 214
CAR-NK cells for cancer immunotherapy: from bench to bedside
Leisheng Zhang, Meng Yuan, Xiaoming Feng, et al.
Biomarker Research (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 134
Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies
Lucila Nassif Kerbauy, Nancy D. Marín, Mecit Kaplan, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 13, pp. 3744-3756
Open Access | Times Cited: 114
NK cells and solid tumors: therapeutic potential and persisting obstacles
Le Tong, Carlos Jiménez‐Cortegana, Apple H.M. Tay, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 100
Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse
Roman M. Shapiro, Grace Birch, Guangan Hu, et al.
Journal of Clinical Investigation (2022) Vol. 132, Iss. 11
Open Access | Times Cited: 86
Exploiting innate immunity for cancer immunotherapy
Ming Yi, Tianye Li, Mengke Niu, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 85
CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors
Lei Peng, Giacomo Sferruzza, Luojia Yang, et al.
Cellular and Molecular Immunology (2024) Vol. 21, Iss. 10, pp. 1089-1108
Open Access | Times Cited: 38
Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells
Mattias Carlsten, Marcus Järås
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 125
Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD
Bruce R. Blazar, Geoffrey R. Hill, William J. Murphy
Nature Reviews Clinical Oncology (2020) Vol. 17, Iss. 8, pp. 475-492
Open Access | Times Cited: 104
You Have Got a Fast CAR: Chimeric Antigen Receptor NK Cells in Cancer Therapy
Aline Pfefferle, Nicholas D. Huntington
Cancers (2020) Vol. 12, Iss. 3, pp. 706-706
Open Access | Times Cited: 96
CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide
Mark E. Gurney, Arwen Stikvoort, Emma Nolan, et al.
Haematologica (2020) Vol. 107, Iss. 2, pp. 437-445
Open Access | Times Cited: 92
Natural killer cell-based immunotherapy for acute myeloid leukemia
Jing Xu, Ting Niu
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 90
A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia
Rosa Nguyen, Huiyun Wu, Stanley Pounds, et al.
Journal for ImmunoTherapy of Cancer (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 89
From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies
Hui Lü, Xiaoyan Zhao, Ziying Li, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 89
Immunotherapy in Acute Myeloid Leukemia: Where We Stand
Alessandro Isidori, Claudio Cerchione, Naval Daver, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 85
A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells
Upasana Sunil Arvindam, P.M.M. van Hauten, Dawn K. Schirm, et al.
Leukemia (2020) Vol. 35, Iss. 6, pp. 1586-1596
Open Access | Times Cited: 80
Modifying the tumour microenvironment and reverting tumour cells: New strategies for treating malignant tumours
Yaqi Cheng, Shou Bi Wang, Jia Hui Liu, et al.
Cell Proliferation (2020) Vol. 53, Iss. 8
Open Access | Times Cited: 79
CXCR4 and anti-BCMA CAR co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model
Yu Yang Ng, Zhicheng Du, Xi Zhang, et al.
Cancer Gene Therapy (2021) Vol. 29, Iss. 5, pp. 475-483
Closed Access | Times Cited: 71
Generating natural killer cells for adoptive transfer: expanding horizons
Soumyadipta Kundu, Mark E. Gurney, Michael O’Dwyer
Cytotherapy (2021) Vol. 23, Iss. 7, pp. 559-566
Open Access | Times Cited: 61
NK Cell Therapy: A Rising Star in Cancer Treatment
Nawen Du, Feifei Guo, Yufeng Wang, et al.
Cancers (2021) Vol. 13, Iss. 16, pp. 4129-4129
Open Access | Times Cited: 60
piggyBac system to co-express NKG2D CAR and IL-15 to augment the in vivo persistence and anti-AML activity of human peripheral blood NK cells
Zhicheng Du, Yu Yang Ng, Shijun Zha, et al.
Molecular Therapy — Methods & Clinical Development (2021) Vol. 23, pp. 582-596
Open Access | Times Cited: 59
Page 1 - Next Page

Scroll to top